PCSK9 Inhibitors and Tirzepatide Show Promise for Diabetes and Heart Health
New ACC findings reveal cardiovascular benefits of PCSK9 inhibitors in diabetes patients and tirzepatide's kidney protection effects.
Cardiovascular health, heart failure, atherosclerosis, and cardiac research
417 articles
New ACC findings reveal cardiovascular benefits of PCSK9 inhibitors in diabetes patients and tirzepatide's kidney protection effects.
New JAMA study shows lifestyle interventions can significantly reduce cardiovascular risk in hypertensive patients.
Landmark 10-year follow-up compares stenting versus bypass surgery for critical left main coronary artery blockages.
New review reveals how telomere shortening drives cardiovascular aging and identifies promising therapeutic targets for heart health.
Comprehensive analysis of cardiovascular disease trends across 204 countries reveals persistent global health challenges.
NEJM publishes erratum for Phase 2a study of baxdrostat in primary aldosteronism treatment
New oral drug MK-0616 matches injectable PCSK9 inhibitors for lowering LDL cholesterol while offering patient-friendly pill form.
Large genetic analysis of 552 adults reveals oral health and cardiovascular disease may not share common genetic pathways as previously thought.
New research shows GDF11, an anti-aging protein, prevents dangerous calcium buildup in arteries by suppressing inflammatory pathways.
New research reveals how specialized immune cells protect the heart during sepsis by enhancing cellular cleanup mechanisms.
New research shows preeclampsia disrupts cardiovascular development in both mothers and babies, creating lasting disease risk.
New study reveals obesity and hypertension, not sleep apnea itself, drive most cardiac changes in OSA patients.